



Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia

Soheila Aminimoghaddam*¹, Forough Nezhadislami¹, Shabnam Anjidani², Saeedeh Barzin Tond¹

Received: 22 Nov 2017

Published: 3 May 2018

Abstract

Background: Gestational trophoblastic neoplasia (GTN) originates from placental trophoblast and is a highly chemosensitive and curable gynecologic malignancy. The present study was conducted to evaluate the effectiveness and safety of EMA/EP (etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin) regimen in the treatment of high-risk GTN as well as patients' outcome.

Methods: Hospital charts of all patients with confirmed diagnosis of high-risk GTN who received EMA/EP regimen treatment during a 12-year period (2001-2012) at the tertiary center of comprehensive women's hospital in Tehran, Iran, were reviewed from 2012 to 2013, retrospectively.

Results: In this study, 25 patients with GTN who were treated with EMA/EP regimen during the study were identified. Complete remission rate in GTN patients with failure of single agent chemotherapy who were treated with EMA/EP regimen, as the first-line treatment, was 100%, while it was 81% in those with primary high-risk GTN. Overall remission rate in high-risk GTN patients treated with EMA/EP regimen was 88%. Anemia (92%) and leucopenia (72%) were the most common adverse effects of EMA/EP chemotherapy regimen. Acute myeloid leukemia (AML) and mortality, as the most severe adverse effects of EMA/EP regimen, were seen only in 1 patient.

Conclusion: According to the results, EMA/EP regimen could induce complete remission in 88% of patients with high-risk GTN. Application of EMA/EP is recommended as the first-line therapy in patients with failure of single agent chemotherapy. However, proper care should be considered to prevent and reduce EMA/EP hematologic toxicity.

Keywords: EMA/EP regimen, Chemotherapy, Gestational trophoblastic neoplasia

Copyright© Iran University of Medical Sciences

Cite this article as: Aminimoghaddam S, Nezhadislami F, Anjidani Sh, Barzin Tond S. Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia approach. *Med J Islam Repub Iran.* 2018(3 May);32:36. <https://doi.org/10.14196/mjiri.32.36>

Introduction

Gestational trophoblastic neoplasia (GTNs) are malignant tumors that originate from placental trophoblast (1). They usually occur following an antecedent pregnancy that may be a term pregnancy, miscarriage, and an ectopic or a molar pregnancy. GTNs often develop following a molar pregnancy (2). The risk of developing GTN following complete hydatidiform mole is approximately 15%, while it is 0.5% to 1% after partial hydatidiform mole (3).

The incidence of GTN is different in different geograph-

ical regions, and it is higher in Asia than in Western countries (4). No accurate data exist on the incidence of GTN in Iran, but its incidence in Turkey has been reported to be 1/1000 deliveries.

GTN is a curable gynecologic malignancy, which is highly sensitive to chemotherapy (5), and its cure rate has increased to 98% by effective treatment (2). Currently, the complete cure rate of about 100% is predictable for non-metastatic and low-risk GTN, while preserving the patient's fertility (6, 7). However, the cure rate ranges from

Corresponding author: Dr Soheila Aminimoghaddam, aminimoghaddam.s@iums.ac.ir

¹ Department of Gynecology and Oncology, Iran University of Medical Sciences, Tehran, Iran.

² Iran University of Medical Sciences, Tehran, Iran.

↑What is "already known" in this topic:

EMA-CO is recommended as the regimen of choice for initial treatment of high-risk GTN. However, 25% to 30% of patients with high-risk GTN still need to undergo salvage chemotherapy. EMA-EP is one of the alternative regimens with a survival rate of up to 84.9%.

→What this article adds:

This study revealed that EMA/EP regimen as the first line treatment could induce complete remission in 88% of patients with high-risk GTN.

80% to 90% in high-risk GTN (8).

Low-risk GTNs are usually treated with single agent chemotherapy, while high-risk GTNs should be treated with chemotherapy. However, about 25% to 30% of GTN tumors are resistant to therapy.

Various agents have been used for combination chemotherapy of high-risk GTN. EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and oncovin®/vincristine) is the most commonly administered first-line combination regimen for high-risk GTN (9, 10). EMA/CO regimen is relatively well-tolerated and has a good cure rate, however, 25% to 30% of patients with high-risk GTN still need further salvage chemotherapy (2, 5), and the results are not satisfactory in metastatic cases (9). Due to the limitations of combination chemotherapy, it is necessary to find an alternative regimen for patients who have failed to respond to available combination agents; also, it is highly important to look for alternative chemotherapeutic regimen without such deficiencies as the first-line treatment.

One of the alternative regimens for EMA/CO is EMA/EP (etoposide, methotrexate, actinomycin D/etoposide, cisplatin) in which cyclophosphamide and vincristine in the EMA/CO are replaced with etoposide and cisplatin.

Due to the higher response rate of EMA/EP, compared to EMA/CO, some authors have suggested EMA/EP as the first-line chemotherapy regimen (11). EMA/EP has been used as a good salvage treatment with a survival rate of up to 84.9% (8). As the first-line treatment, EMA/EP has been reported to have survival rate of 88% in high-risk GTN (12). However, limited data are available about the efficacy and toxicity of EMA/EP regimen in the treatment of high-risk GTN.

The present study was conducted to investigate the efficacy and safety of EMA/EP regimen in the treatment of high-risk GTN as well as the patients' outcomes.

Methods

This was a retrospective review of hospital records of all patients with high-risk GTN treated with EMA/EP regimen

as the first-line treatment during a 12-year period (2001-2012) at the tertiary center of comprehensive women's hospital in Tehran, Iran.

The study protocol was approved by the Institutional Review Board (IRB) of Iran University of Medical Sciences (ethical number: IR.IUMS.FMD.REC. 1392.801011133).

Hospital records of all patients who referred to the gynecology-oncology ward of our hospital from 2001 to 2012 were screened. Demographic data and gynecological and obstetrical history, such as gravidity, parity, abortion, and treatment side effects, were recorded using questionnaires. Anatomical and clinical staging system was performed following the confirmation of persistent GTN with rising or plateau of serum β -HCG concentration. When the disease was confined to the uterus, stage I or nonmetastatic form was perceived; on the other hand, when a metastatic lesion was detected in the vagina, lung, etc., stage II, III, or IV were considered. Disease scoring was done according to WHO (World Health Organization) scoring system, which included age, duration of the disease, prior pregnancy type, serum β -HCG titer, size and number of metastasis. Patients with the risk score of 7 or greater were categorized as having high-risk GTN and those who obtained the score of 6 or less as having low-risk GTN.

Two groups of patients were included in the study who received EMA/EP regimen:

(1) Patients with risk score of 7 or greater based on modified WHO and FIGO (International Federation of Gynecology and Obstetrics) scoring system, and (2) those whose initial single agent chemotherapy failed (high-risk GTN) and had GOG (Gynecologic Oncology Group) performance status of less than 3 with normal primary CBC (complete blood count), liver, and kidney test.

Patients with chronic liver or kidney disease or other diagnoses were excluded.

In this study, 25 patients with high-risk GTN who were treated with EMA/EP regimen were identified during April 2001 and April 2012.

To evaluate response to treatment, serum β -HCG was measured every 2 weeks using radioimmunoassay method,

Table 1. EMA/EP chemotherapy regimen in patients with high-risk GTN with and without brain and liver metastasis

Time	Regimen	Protocol
For high-risk GTN without brain metastasis		
First day	Etoposide (vp-16)	100 mg/m ² in 500 ml normal saline by IV infusion over 30 min
First day	Actinomycin	0.5mg IV stat
First day	Methotrexate	100mg/m ² IV stat
First day	Methotrexate	200 mg/m ² in 500-1000 ml normal saline by IV infusion over 12 hours
Second day	Etoposide (vp-16)	100 mg/m ² in 500 ml normal saline by IV infusion over 30 min
Second day	Actinomycin_D	0.5 mg IV stat
Second day	Citrovorum factor rescue	15 mg IM/PO every 12 hours, 4 doses to start 24 hours commencement of methotrexate
Eighth day	Etoposide (vp-16)	100 mg/m ² in 500 ml normal saline by IV infusion over 30 min
Eighth day	Cisplatin	60-80 mg/m ² IV
For high-risk GTN with brain metastasis		
First day	Etoposide (vp-16)	100 mg/m ² in 500 ml normal saline by IV infusion over 30 min
First day	ActinomycinD	0.5 mg IV stat
First day	Methotrexate	100 mg/m ² IV stat
First day	Methotrexate	1000 mg/m ² in 500-1000 ml normal saline by IV infusion over 12 hours
Second day	Etoposide (vp-16)	100 mg/m ² in 500 ml normal saline by IV infusion over 30 min
Second day	ActinomycinD	0.5 mg IV stat
Second day	Citrovorum factor rescue	30 mg IM/PO every 12 hours, 6 doses to start 24 hours commencement of methotrexate
Eighth day	Etoposide (vp-16)	100 mg/m ² in 500 ml normal saline by IV infusion over 30 min
Eighth day	Cisplatin	60-80 mg/m ² in 100 ml normal saline by IV infusion (not to exceed 1 mg/min)
Repeated course on days 15, 16, and 22		

and a serum β -HCG level <5 IU/L (normal level) for 3 consecutive weeks was considered as positive response to the treatment or remission.

EMA/EP chemotherapy was started (Table 1) for the patients and continued until serum β -HCG levels reached the normal level (<5 IU/L). Then, 1 to 3 additional courses of consolidation chemotherapy were administered for 6 weeks. Chemotherapy courses were repeated every 2 weeks during the course of treatment.

The remission rate of the disease was evaluated by β -HCG level and documented in patients' medical records. Moreover, the safety and efficacy of the treatment were measured according to NCI Common Terminology Criteria for Adverse Events (CTCAE). Patients with confirmed brain metastasis received high-dose regimen (Table 1). They also received concurrent radiotherapy of 3000 cGy to the whole brain.

All patients received GCSF (granulocyte colony-stimulating factor) 24 hours after completion of EMA/EP chemotherapy course and continued taking it up to 24 hours before the next course of chemotherapy to prevent or reduce hematologic complications of the treatment.

Chemotherapy tolerance, remission, recurrence, and toxicity were monitored during the treatment period. Moreover, recurrence, treatment complications, and toxicity were recorded after remission.

Statistical analysis

Data were analyzed using SPSS software version 17.0 for Windows. Continuous data were expressed as mean \pm SD and categorical data as number and percent. P- value less

than 0.05 was considered as statistically significant.

Results

The mean age of the patients was 30.0 ± 6.1 years (range: 18-44). Demographic characteristics of the patients are demonstrated in Table 2. Most GTN patients (68%) were in the stage III of the disease with lung metastasis based on FIGO anatomical staging. Moreover, most of GTN tumors occurred following molar pregnancy (48%) (Table 2). Precedent pregnancies were terminated by D&C (dilatation and curettage) in 76% (19) of patients, vaginal delivery in 20% (5), and salpingectomy in 4% (1). Type of GTN pathology was unknown in most patients (Table 2). Uterine mass was detected in 16 of 20 patients (84%), and tumor size was less than 5 cm in 52% of the cases (11). Four patients underwent hysterectomy, of which 3 had the tumor size of greater than 5 cm.

A total of 78 courses of EMA/EP chemotherapy and 44 consolidation courses were given (Table 3). The main therapeutic outcome was remission rate. Remission rate in the metastatic group was 88% and it was 100% in the non-metastatic group (Table 3). After failure of monotherapy, total chemotherapy courses were less in patients (the second group of patients) than those with primary high-risk GTN (the first group of included patients) (Table 3).

The most common toxicity of EMA/EP regimen was myelosuppression, including anemia and leucopenia, which were observed in 92% and 72% of the patients, respectively (Table 4).

Table 2. Demographic characteristics of patients with high-risk GTN

Variable	Value (n=25)
Gravid	1-4 20(80)
	5-8 5(20)
Para	Yes 22(88)
	No 3(12)
Abortion	Yes 11(44)
	No 14(56)
Live birth	Yes 21(84)
	No 4(16)
Mole	Yes 16(64)
	No 9(36)
FIGO anatomical staging	
Stage 1. disease confined to the uterus	5(20)
Stage 2. GTN extends to the genital structures	0 (0)
Stage 3. lung metastasis	17 (68)
Stage 4. liver and/or brain metastasis	3 (12)
Indication for treatment	
Failure of single-agent therapy	9 (36)
Primary high-risk GTN	16 (64)
Antecedent pregnancy	
Hydatiform mole	12 (48)
Term pregnancy	8 (32)
Non-molar abortion	4 (16)
Ectopic pregnancy	1 (4)
Pathology	
Choriocarcinoma	8 (3)
Extrauterine choriocarcinoma,	1(4)
Unknown	16 (64)
Therapeutic Surgery for GTN	
Hysterectomy	4 (16)
Nephrectomy	1 (4)
Thoracotomy	2 (16)

Data is given as n (%)

Table 3. Remission rate in patients treated with EMA/EP regimen as the first- line therapy

	n	CRR N (%)	No. of EMA-EP and EMA chemotherapy courses to disease remission (me- dian)	No. of consolidation chemotherapy courses (median)
Single-agent chemotherapy failure	9	9 (100)	2 (1-3) ^a	2 (0-3)
Primary high risk GTN (WHO risk score \geq 7)	16	13 (81)	3 (2-10) ^b	2 (0-3)
Total	25	22 (88)	3 (1-10)	2 (0-3)

CRR: complete remission rate

^a median (range)^b Only 1 patient who was at the beginning of treatment and received multiple treatment courses (10 courses) died.

Table 4. Toxicity profile of EMA/EP chemotherapy regimen in patients

Toxicity	n (%)
Myelosuppression	
Anemia	
No anemia	2 (8%)
Grade 1 anemia	7 (28%)
Grade 2 anemia	10 (40%)
Grade 3 anemia	4 (16%)
Grade 4 anemia	2 (8%)
Leukopenia	
No leukopenia	7 (28%)
Grade 1 leukopenia	2 (8%)
Grade 2 leukopenia	9 (36%)
Grade 3 leukopenia	7 (28%)
Thrombocytopenia	
Blood transfusion	13 (52%)
Platelet transfusion	4 (16%)
Severe life-threatening infection	2 (8%)
Alopecia	14 (56%)
Transaminase rise	3 (12%)
Gastrointestinal toxicity	
Heavy nausea and vomiting	1 (4%)
Diarrhea	1 (4%)
Osteomyelitis	15 (60%)
Dose reduction	7 (28%)
Delay in courses	3 (12%)
Secondary malignancy	1 (4%)
Death	1 (4%)

One patient expired due to acute myeloid leukemia (AML), which is the most severe adverse effect of EMA/EP regimen.

Discussion

This study showed the significant efficacy of EMA/EP chemotherapy regimen as the first- line therapy in the treatment of high-risk GTN. Overall remission rate in GTN patients treated with EMA/EP was 88%, while complete remission rate of 100% was observed in patients with failure of single agent chemotherapy in primary low-risk score or stage 1. The most common observed toxic effects of EMA/EP regimen were anemia and leucopenia.

Considering the limitations of EMA/CO, some authors have suggested to use the EMA/EP regimen as the first- line therapy for high-risk GTN. In the first study on this topic by Ghaemmaghami et al. (12) in Iran, 17 patients with high-risk metastatic GTN were treated with EMA/EP regimen as the first- line therapy from 2000 to 2003. In their study, overall remission rate with EMA/EP chemotherapy as the first- line therapy was 88% and 100% in patients who completed chemotherapy. This rate was similar to ours because the treatment regimen and protocol was the same. The only difference of that study with ours was in the studied patients. They selected patients with metastatic high-risk GTN, and we selected both metastatic and non-metastatic GTN patients. Moreover, they included patients with WHO risk score of \geq 6, while we selected those with a risk score of \geq 7. However, the results are comparable in both studies.

In Ghaemmaghami et al. study, similar to ours, anemia and leukopenia were the most common toxicities of EMA/EP regimen, while the rate of these adverse effects in our study was higher than their study and resulted in higher rate of blood transfusion. Although the rate of neutropenia in our study was less than theirs, the need for platelet transfusion in patients was higher in our study than in Ghaemmaghami et al. study. However, the rate of adverse hepatic effects of EMA/EP in both studies was similar. Inclusively, due to equal sample sizes of the high-risk group in Ghaemmaghami et al. and ours, the overall remission rate was the same (12).

In India, Cyriac S et al. (11) evaluated 9 patients with very high-risk GTN who received the EMA/EP regimen as the frontline therapy. The overall survival rate was reported to be 66.7% and all patients with lung or lung and liver metastasis survived. They concluded that EMA/EP regimen is highly effective in the treatment of patients with high-risk GTN. Remission rate was lower than our study, which may be due to the smaller sample size or other protocol factors.

Hann SN et al. (13) assessed the safety and efficacy of EMA/EP regimen as the first- line therapy or salvage chemotherapy in 18 patients with high-risk GTN. Complete remission rate was 89%, which was similar to our study. In that study, anemia and neutropenia occurred in all patients (100%). In their study, 2 patients (11%) died due to progressive disease and sepsis and endocarditis. However, mortality rate was 4% in our study. They concluded that EMA/EP with high remission rate and moderate toxicity is

an excellent regimen for the treatment of high-risk GTN.

EMA/EP regimen has been associated with other toxic effects including myelosuppression and hepatotoxicity, which lead to delaying the treatment and dosage reductions. Administration of granulocyte-colony stimulating factor (G-CSF) to the patients may prevent or reduce myelosuppression and hematologic adverse effects of EMA/EP (2, 14, 15). In our study, the rate of myelosuppression with EMA/EP regimen was high although all patients received G-CSF. It is a regimen with a high rate of cure that outweighs its toxicity.

The limitation of this study was its retrospective nature, and thus conducting randomized controlled trials is highly suggested for more accurate evaluations.

Conclusion

According to the results, EMA/EP regimen as the first line-treatment could induce complete remission in 88% of patients with high-risk GTN. In the previous regimen (EMA/CO), Oncovin (vincristine) was associated with constipation and extravasation and induced skin necrosis. Cyclophosphamide induces hemorrhagic cystitis. One of the late side effects of chemotherapy regimens, including etoposide, is leukemia, which could lead to mortality. Application of EMA/EP may be recommended as the first-line therapy in high-risk GTN patients, especially in patients with failure of single agent chemotherapy. However, necessary steps should be taken to prevent and reduce EMA/EP toxic effects that are tolerable in general.

Conflict of Interests

The authors declare that they have no competing interests.

References

1. Aminimoghaddam S, Yarandi F, Nejadsalami F, Taftachi F, Noorbakhsh F, Mahmoudzadeh F. Human chorionic gonadotrophin as an indicator of persistent gestational trophoblastic neoplasia. *Med J Islam Repub Iran*. 2014;28(1):272-5.
2. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. *Lancet*. 2010;376(9742):717-29.
3. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. *Lancet Oncol*. 2003;4(11):670-8.
4. Aminimoghaddam S, Maghsoudnia A. Unusual Presentation of Invasive Mole: A Case Report. *J Reproduct Infertilit*. 2017;18(1):205-9.
5. Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. *Am J Obstet Gynecol*. 2011;204(1):11-8.
6. Yarandi F, Mousavi A, Abbaslu F, Aminimoghaddam S, Nekuie S, Adabi K, et al. Five-Day Intravenous Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial. *Int J Gynecol Cancer*. 2016;26(5):971-6.
7. Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. *J Clin Oncol*. 2013;31(2):280-6.
8. Mao Y, Wan X, Lv W, Xie X. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. *Int J Gynaecol Obstet*. 2007;98(1):44-7.
9. Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. *J Clin Oncol*. 1997;15(7):2636-43.

10. Deng L, Zhang J, Wu T, Lawrie TA. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. *Cochrane Database Syst Rev*. 2013;1:CD005196.
11. Cyriac S, Rajendranath R, Sridevi V, Sagar TG. Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia. *Int J Gynaecol Obstet*. 2011;115(1):37-9.
12. Ghaemmaghami F, Modares M, Arab M, Behtash N, Moosavi AZ, Khanafshar N, et al. EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV). *Int J Gynecol Cancer*. 2004;14(2):360-5.
13. Han SN, Amant F, Leunen K, Devi UK, Neven P, Vergote I. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia. *Int J Gynecol Cancer*. 2012;22(5):875-80.
14. Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. *Gynecol Oncol*. 2005;97(2):618-23.
15. El-Helw LM, Seckl MJ, Haynes R, Evans LS, Lorigan PC, Long J, et al. High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. *Br J Cancer*. 2005;93(6):620-1.